Clinical trial
A New Biomarker-Based Approach Towards Developing Improved Treatment for Major Depressive Disorder (MDD) Based Upon Targeting Monoamine Oxidase A (MAO-A)
NCT02269540 is registered in ClinicalTrials.gov with Centre for Addiction and Mental Health as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A New Biomarker-Based Approach Towards Developing Improved Treatment for Major Depressive Disorder (MDD) Based Upon Targeting Monoamine Oxidase A (MAO-A)
- Lead sponsor
- Centre for Addiction and Mental Health
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- October 31, 2014
- Completion date
- July 31, 2018
- Enrollment
- 10 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.